Effects of imiglucerase treatment on traumatic fracture and bone and blood abnormalities in a patient with previously untreated type 1 gaucher disease.
OBJECTIVE
This letter reports on the effect of enzyme replacement therapy with imiglucerase on bone healing and bone and blood abnormalities in a woman with previously untreated type 1 Gaucher disease (GD).


METHODS
The 49-year-old patient had been diagnosed with GD at the age of 28 years and had previously undergone splenectomy. She presented with pseudarthrosis 14 months after sustaining a traumatic fracture of the tibia and fibula. Therapy was begun with imiglucerase 60 U/kg q2wk. The effects of treatment on bone healing were monitored radiographically, and effects on blood and bone marrow biology were monitored by hemograms, myelograms, and hematopoietic and mesenchymal clonogenic assays.


RESULTS
Objective bone healing was observed starting in the third month of imiglucerase treatment. Blood abnormalities normalized and bone marrow parameters improved over the first 9 months, including a decrease in Gaucher cells, an increase in bone marrow CD34+ cell cloning efficiency, and the appearance of mesenchymal progenitors.


CONCLUSIONS
This research letter reports the results of hematologic and bone evaluations during enzyme replacement therapy with imiglucerase in a woman with previously untreated type 1 GD who presented with a traumatic fracture.
Boiret-Dupré
Nathalie
N
Service d'Hématologie Biologique-Immunologie, CHU, Clermont-Ferrand, France.
Descamps
Stéphane
S
Coudoré
Marie Ange
MA
Rapatel
Chantal
C
Kuentz
Mathieu
M
Pereira
Sylvie
S
Tournadre
Josiane
J
Berger
Juliette
J
Morell
Philippe
P
Berger
Marc G
MG
D000058:Accidental Falls; D001854:Bone Marrow Cells / Q000473:pathology; D056947:Enzyme Replacement Therapy; D005260:Female; D005360:Fibula / Q000000981:diagnostic imaging / Q000293:injuries*; D005593:Fracture Fixation, Internal; D017102:Fracture Healing; D005776:Gaucher Disease / Q000097:blood / Q000150:complications / Q000201:enzymology / Q000628:therapy*; D005962:Glucosylceramidase / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000097:blood / Q000201:enzymology / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D011542:Pseudarthrosis / Q000000981:diagnostic imaging / Q000201:enzymology / Q000209:etiology / Q000628:therapy*; D011859:Radiography; D013978:Tibial Fractures / Q000150:complications / Q000000981:diagnostic imaging / Q000201:enzymology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome
D005962:Glucosylceramidase; C090568:imiglucerase